Show Summary Details
Page of

Cancer chemotherapy and radiation therapy 

Cancer chemotherapy and radiation therapy

Chapter:
Cancer chemotherapy and radiation therapy
Author(s):

Bruce A. Chabner

and Jay Loeffler

DOI:
10.1093/med/9780199204854.003.0606_update_004

Update:

Thorough updates include discussion of

(1) drugs that target protein degradation pathways, including proteasome inhibitors and ubiquitin ligase inhibitors in treatment of myeloma;

(2) a growing array of targeted drugs to treat haematological malignancies;

(3) use of hypofractionated radiation therapy schemes (higher dose per day, less fractions).

Updated on 30 Jul 2015. The previous version of this content can be found here.
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2015. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy).

date: 27 June 2017

The last two decades have brought significant improvements in cancer therapy: patients with previously fatal diseases, including acute leukaemia, non-Hodgkin’s lymphoma, Hodgkin’s disease, and germ cell tumours, now have a high expectation of cure. For patients with the more common solid tumours, including lung, colon, and breast cancer, new chemotherapeutic and hormonal agents, molecularly targeted drugs, and monoclonal antibodies have improved treatment of both early and late stage disease and have extended survival. Nevertheless, cancer remains the second leading cause of death in the Western world, and nearly one third of patients diagnosed with cancer will die of their disease....

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.